Status:
COMPLETED
Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients
Lead Sponsor:
Tanta University
Conditions:
Anesthesia
Obesity, Morbid
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
Compare the effects of two different doses of dexmedetomidine infusion on oxygenation as a primary outcome and on lung mechanics, quality of recovery and perioperative analgesia as secondary outcomes ...
Detailed Description
Dexmedetomidine is a selective α2 receptor agonist and has sympatholytic, analgesic, anti-inflammatory and sedative properties. Dexmedetomidine decreased dead space and improved both lung compliance a...
Eligibility Criteria
Inclusion
- Body Mass Index above 40 kg/m2 with restrictive lung disease((forced vital capacity) \<70% in pre-operative pulmonary function tests), of American Society of anesthesiologists (ASA) physical status II and III.
- Aged 18-50 years.
- Scheduled for abdominal surgery.
Exclusion
- Patients with Forced expiratory volume1/forced vital capacity\<7.
- Uncontrolled cardiac, respiratory, hepatic or renal diseases.
- Allergy to the study drug
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06018948
Start Date
September 1 2019
End Date
September 30 2021
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527